Merck Hits Barr With Suit Over Generic Fosamax

Law360, New York (June 6, 2006, 12:00 AM EDT) -- Continuing its campaign to protect blockbuster osteoporosis drug Fosamax, Merck & Co.’s has filed another suit against a generic maker seeking to market its own version of the drug.

Merck has filed a declaratory judgment suit against generics maker Barr Laboratories, claiming that Barr has filed an Abbreviated New Drug Application for alendronate sodium tablets, the active ingredient in Fosamax, and that Barr’s production of the tablets will violate several patents held by Merck.

In the suit, filed in the U.S. District Court for the District...
To view the full article, register now.